OVERLAND PARK, Kan., Feb. 12, 2015 (GLOBE NEWSWIRE) -- Parnell Pharmaceuticals Holdings Ltd. (Nasdaq: PARN ), a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions, announced today that on February 25, 2015 at 7:00 am ET it will report financial results for the six-month period ended December 31, 2014. The six-month reporting period is part of a previously announced transition to reporting financial results on a calendar year basis (previously June 30 year-end).
Management will host a conference call on February 25, 2015 at 8:00 a.m. ET to discuss financial results and answer questions. Investors and analysts may access the conference call by dialing (877) 244-6184 (U.S./Canada) or (920) 663-6271 (International) and using the conference ID#86814336.
Please dial-in approximately 10 minutes in advance to facilitate an on-time start.
A telephone replay will be available for one week following the call by dialing (855) 859-2056 (U.S./domestic) and (404) 537-3406 (International) using the conference ID# 86814336.
A copy of the company's earnings release will be furnished to the Securities and Exchange Commission on a Form 6-K and posted on Parnell's website at http://investors.parnell.com/releases.cfm prior to the call.
About Parnell
Parnell (Nasdaq: PARN ) is a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative animal health solutions. Parnell currently markets five products for companion animals and production animals in 14 countries and augments its pharmaceutical products with proprietary software platforms - iKAM and mySYNCH. These innovative technology solutions are designed to enhance the quality of life or performance of animals, while driving customers' operational efficiency and profitability. Parnell believes its value-added solutions help establish them as a business partner with customers rather than only as a commodity provider, differentiating them from competitors.
For more information on the company and its products, please visit www.parnell.com .
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements and information within the meaning of the U.S. Private Securities Reform Act of 1995. Words such as "may," "anticipate," "estimate," "expects," "projects," "intends," "plans," "develops," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. Forward-looking statements represent management's present judgment regarding future events and are subject to a number of risk and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding Parnell's research and development activities, its ability to conduct clinical trials of product candidates and the results of such trials, as well as risks and uncertainties relating to litigation, government regulation, economic conditions, markets, products, competition, intellectual property, services and prices, key employees, future capital needs, dependence on third parties, and other factors, including those described in Parnell's Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on September 15, 2014, along with our other reports filed with the SEC. In light of these assumptions, risks, and uncertainties, the results and events discussed in the forward-looking statements contained in this press release might not occur. Investors are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Parnell is under no obligation, and expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, contact: Parnell Pharmaceuticals Holdings Robert Joseph, 913-274-2100 BCC Partners Karen Bergman, 650-575-1509 Susan Pietropaolo, 845-638-6290
